Your browser doesn't support javascript.
loading
Impact of opioid therapy on gonadal hormones: focus on buprenorphine.
Varma, Anjali; Sapra, Mamta; Iranmanesh, Ali.
Afiliación
  • Varma A; Mental Health Clinic, Lead Psychiatrist Buprenorphine Clinic, Veterans Affairs Medical Centre, 1970 Roanoke Blvd., Salem, VA, USA, Phone: +5409822463, ext 3555, Fax: +540-855-3452.
  • Sapra M; Department of Psychiatry and Behavioral Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA, USA.
  • Iranmanesh A; Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, Roanoke, VA, USA.
Horm Mol Biol Clin Investig ; 36(2)2018 Feb 17.
Article en En | MEDLINE | ID: mdl-29453925
Objective The USA is in the midst of an opioid crisis. Understanding the impact of opioids and commonly used treatments for opioid dependence is essential for clinicians and researchers in order to educate and treat the nation's growing population with opioid use disorders. As a relatively new treatment for opioid dependence, buprenorphine is gaining popularity to the extent of becoming not only a preferred approach to the maintenance of opiate addiction, but also an option for chronic pain management. The purpose of this report is to review the available evidence on the endocrine effects of buprenorphine, particularly as it relates to the hypothalamic-pituitary-gonadal (HPG) axis, which is controversial and not fully defined. Method We conducted a Pubmed search (2000-2017) for human studies in the English language for articles that were available as full length regarding buprenorphine, endocrinopathy, hypogonadism, bone density, opioids. Case reports were also reviewed, although prospective studies and randomized controlled trials received more weight. Results Opioid induced hypogonadism is well established. Most studies report that buprenorphine being a partial agonist/antagonist may not be impacting the pituitary trophic hormones as much. There are reports of sexual dysfunction in subjects maintained on buprenorphine, some without hormonal correlation. Thus with the understanding that pertinent clinical studies are limited in number, varied in methodology, mostly cross sectional, predominantly in men and small number of participants, more research in this area is warranted. Conclusion Based on a comprehensive review of the available literature, we conclude that despite its increasing popularity, buprenorphine has not been adequately studied in respect to its long-term effects on the hypothalamic-pituitary-adrenal (HPA) axis. There is a great need for longitudinal systematic trials to define the potential buprenorphine-induced endocrine consequences.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Buprenorfina / Hormonas Gonadales / Tratamiento de Sustitución de Opiáceos / Antagonistas de Narcóticos Tipo de estudio: Clinical_trials / Observational_studies Límite: Animals / Humans Idioma: En Revista: Horm Mol Biol Clin Investig Año: 2018 Tipo del documento: Article Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Buprenorfina / Hormonas Gonadales / Tratamiento de Sustitución de Opiáceos / Antagonistas de Narcóticos Tipo de estudio: Clinical_trials / Observational_studies Límite: Animals / Humans Idioma: En Revista: Horm Mol Biol Clin Investig Año: 2018 Tipo del documento: Article Pais de publicación: Alemania